These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 9141798

  • 1. Adverse drug reaction monitoring in pediatric practice.
    Kshirsagar NA, Karande S.
    Indian Pediatr; 1996 Dec; 33(12):993-8. PubMed ID: 9141798
    [No Abstract] [Full Text] [Related]

  • 2. International monitoring for adverse drug reactions of long latency.
    Fletcher AP, Griffin JP.
    Adverse Drug React Toxicol Rev; 1991 Dec; 10(4):209-30. PubMed ID: 1793771
    [No Abstract] [Full Text] [Related]

  • 3. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment.
    Ferranti J, Horvath MM, Cozart H, Whitehurst J, Eckstrand J.
    Pediatrics; 2008 May; 121(5):e1201-7. PubMed ID: 18450863
    [Abstract] [Full Text] [Related]

  • 4. Strategy for surveillance of adverse drug events.
    Bright RA.
    Food Drug Law J; 2007 May; 62(3):605-16. PubMed ID: 17915403
    [No Abstract] [Full Text] [Related]

  • 5. Research methods in drug surveillance.
    Engel RR, Grohmann R, Rüther E, Hippius H.
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [Abstract] [Full Text] [Related]

  • 6. [Drug-eruptions].
    Thielen AM, Toutous-Trellu L, Desmeules J.
    Rev Med Suisse; 2008 Jul 16; 4(165):1671-5. PubMed ID: 18767294
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J, Donnan PT.
    Pharmacoepidemiol Drug Saf; 2001 Jul 16; 10(4):341-4. PubMed ID: 11760497
    [No Abstract] [Full Text] [Related]

  • 13. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL.
    J Natl Cancer Inst; 2005 Jun 15; 97(12):872-3. PubMed ID: 15956645
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Development, testing, and findings of a pediatric-focused trigger tool to identify medication-related harm in US children's hospitals.
    Takata GS, Mason W, Taketomo C, Logsdon T, Sharek PJ.
    Pediatrics; 2008 Apr 15; 121(4):e927-35. PubMed ID: 18381521
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R, Wyeth J, Chen M, Cope JU.
    Pharmacoepidemiol Drug Saf; 2009 Jan 15; 18(1):24-7. PubMed ID: 19009550
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.